TG Therapeutics (NASDAQ:TGTX) Upgraded at BidaskClub

BidaskClub upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a research note released on Thursday, BidAskClub reports.

Other equities analysts have also recently issued reports about the stock. B. Riley reaffirmed a buy rating on shares of TG Therapeutics in a research note on Tuesday, June 11th. Zacks Investment Research raised shares of TG Therapeutics from a sell rating to a hold rating in a research note on Tuesday, August 6th. ValuEngine raised shares of TG Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $17.00 price objective on shares of TG Therapeutics in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $14.07.

TGTX opened at $6.84 on Thursday. TG Therapeutics has a one year low of $3.32 and a one year high of $12.90. The company has a debt-to-equity ratio of 2.77, a current ratio of 1.69 and a quick ratio of 1.72. The company’s 50 day simple moving average is $7.69 and its 200-day simple moving average is $7.06.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. On average, equities analysts anticipate that TG Therapeutics will post -1.53 EPS for the current fiscal year.

In other news, CFO Sean A. Power sold 17,654 shares of TG Therapeutics stock in a transaction on Monday, July 1st. The shares were sold at an average price of $8.47, for a total transaction of $149,529.38. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael S. Weiss purchased 50,000 shares of TG Therapeutics stock in a transaction dated Wednesday, June 26th. The shares were purchased at an average cost of $7.04 per share, for a total transaction of $352,000.00. The disclosure for this purchase can be found here. 14.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock worth $45,883,000 after purchasing an additional 866,572 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock worth $34,955,000 after purchasing an additional 665,380 shares in the last quarter. Sofinnova Investments Inc. boosted its position in shares of TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock worth $10,911,000 after purchasing an additional 909,573 shares in the last quarter. Camber Capital Management LP bought a new position in shares of TG Therapeutics during the second quarter worth $8,650,000. Finally, Artal Group S.A. boosted its position in shares of TG Therapeutics by 12.5% during the second quarter. Artal Group S.A. now owns 900,000 shares of the biopharmaceutical company’s stock worth $7,785,000 after purchasing an additional 100,000 shares in the last quarter. 54.48% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Story: Quantitative Easing

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.